✦ LIBER ✦

Cellular immune competence in patients with transitional cell carcinoma of the bladder

✍ Scribed by Batya Shohat; Haim Perry; Ciro Servadio

Book ID: 118373390
Publisher: Elsevier Science
Year: 1978
Tongue: English
Weight: 335 KB
Volume: 10
Category: Article
ISSN: 1090-2341
DOI: 10.1016/0090-1229(78)90011-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cellular fibronectin in patients with tr

Cellular fibronectin in patients with transitional cell carcinoma of the bladder

✍ Axel Hegele; Axel Heidenreich; Zoltan Varga; Rolf von Knobloch; Peter Olbert; Jü 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 180 KB

Transitional cell carcinoma of bladder i

Transitional cell carcinoma of bladder in pediatric patients

✍ Sandra BATTAGLIA Francesca DIOMEDI CAMASSEI∗; Nicola CAPOZZA; Paolo CAIONE 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Cell-mediated tumour immunity in patient

Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder

✍ J. Bubeník 📂 Article 📅 1975 🏛 Springer Netherlands 🌐 English ⚖ 399 KB

Immunological Profile of Patients with T

Immunological Profile of Patients with Transitional Cell Carcinoma of the Bladder

✍ E. MUKAMEL; B. SHOHAT; C. SERVADIO 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Recurrence risk factors in patients with

Recurrence risk factors in patients with transitional cell carcinoma of bladder

✍ Xiang-hui Yue; Xiao-hong Yang; Fu-qing Zheng 📂 Article 📅 2005 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 409 KB

Adjuvant Bestatin immunotherapy in patie

Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder

✍ Henric Blomgren; Ingemar Näslund; Pier-Luigi Esposti; Lise Johansen; Ove Aaskove 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 554 KB

The first clinical results of an ongoing, prospective trial to determine the value of adjuvant Bestatin immunotherapy in the management of bladder cancer are presented. Patients with nonmetastatic transitional cell carcinoma of the bladder, scheduled for full dose local radiation therapy (64 Gy), we